Compare SER & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SER | CELU |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3M | 34.5M |
| IPO Year | 2018 | N/A |
| Metric | SER | CELU |
|---|---|---|
| Price | $1.70 | $1.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $13.00 | $6.00 |
| AVG Volume (30 Days) | ★ 3.6M | 33.0K |
| Earning Date | 03-23-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $116,000.00 | ★ $40,578,000.00 |
| Revenue This Year | $134.46 | N/A |
| Revenue Next Year | N/A | $76.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.71 | $1.00 |
| 52 Week High | $7.92 | $4.35 |
| Indicator | SER | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 31.98 | 42.44 |
| Support Level | $2.11 | $1.17 |
| Resistance Level | $3.14 | $1.33 |
| Average True Range (ATR) | 0.35 | 0.07 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 2.03 | 25.00 |
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.